Showing 121–132 of 208 resultsSorted by latest
Pharma & Biotech
Roche is based in Basel, Switzerland, specializing in pharmaceuticals and diagnostics.
NetScout’s advancing cybersecurity capabilities and addressing the evolving threat landscape.
In September 2024, Hurricane Helene caused significant rain and flooding in Western North Carolina, damaging assets and disrupting operations at Baxter’s North Cove facility in Marion, N.C.
Amgen continues to perform well with strong growth in oncology, rare diseases, and inflammation. Drugs like Repatha, EVENITY, TEZSPIRE, and TEPEZZA are expanding their market reach, and new biosimilars, such as PAVBLU, WEZLANA, and BEKEMV, will further strengthen their position
United Therapeutics (UTHR) is a biotechnology company focused on developing and commercializing innovative therapies for patients with serious diseases, particularly pulmonary arterial hypertension (PAH) and cancer.
In the third quarter of 2024, Gilead’s total product sales increased by 7% to $7.5 billion compared to the same period in 2023.
MRK is launching important new products that address unmet medical needs and have significant commercial potential.
In Q3, Thermo Fisher’s pharma and biotech segment declined slightly, down in the low single digits, mainly due to the decrease in vaccine and therapy revenue.
LEQEMBI’s revenue in the U.S. is still below Biogen’s expectations, and the prescriber base hasn’t grown as much as anticipated.
Abbott achieved several key milestones in its biosimilars portfolio, with the first biosimilar set to launch in emerging markets by late 2025
Johnson & Johnson has recently acquired Shockwave and V-Wave in MedTech, along with Ambrx, Proteologix, and NM26 in Innovative Medicine.
ADMA is a commercial biopharmaceutical company focused on manufacturing, marketing, and developing speciality biologics to treat immunodeficient patients and others at risk for infections.